Tardive dyskinesia - Pipeline Insight, 2024

This Tardive dyskinesia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tardive dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tardive dyskinesia Understanding

Tardive dyskinesia: Overview

Tardive dyskinesia (TD) is a syndrome that encompasses a constellation of iatrogenic movement disorders caused by antagonism of dopamine receptors. The movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements. Most often, these dyskinetic disorders precipitate following chronic antipsychotic administration, however, several other medications are also associated with tardive dyskinesia. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) defines tardive dyskinesia as a medication-induced movement disorder that persists despite discontinuation or change of the medications. As per DSM-V, to confirm a diagnosis of tardive dyskinesia, symptoms must persist for at least one month after discontinuation of the medication.

Tardive dyskinesia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tardive dyskinesia pipeline landscape is provided which includes the disease overview and Tardive dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Tardive dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tardive dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Tardive dyskinesia. The therapies under development are focused on novel approaches to treat/improve Tardive dyskinesia.

Tardive dyskinesia Emerging Drugs

SOM3366: SOM BiotechSOM3366 is an oral VMAT2 inhibitor (vesicular monoamine transporter 2) for the symptomatic treatment of Tardive Dyskinesia (TD). SOM3366 is currently finishing preclinical development in TD, with Phase 1 clinical trial initiation expected in 2022.

Tardive dyskinesia: Therapeutic Assessment

This segment of the report provides insights about the Tardive dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tardive dyskinesia

There are approx. 5+ key companies which are developing the therapies Tardive dyskinesia. The companies which have their Tardive dyskinesia drug candidates in the most advanced stage, i.e Phase III include, Mitsubishi Tanabe Pharma.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tardive dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tardive dyskinesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tardive dyskinesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tardive dyskinesia drugs.

Tardive dyskinesia Report Insights

• Tardive dyskinesia Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tardive dyskinesia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tardive dyskinesia drugs?
• How many Tardive dyskinesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tardive dyskinesia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tardive dyskinesia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tardive dyskinesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Addex Therapeutics
• Contera Pharma
• Teva Pharmaceutical
• SOM Biotech
• Mitsubishi Tanabe Pharma

Key Products

• Dipraglurant
• CP-011
• Deutetrabenazine
• SOM3366
• MT-5199

This product will be delivered within 2 business days.